Literature DB >> 28108230

Timeliness and risk factors associated with delay for pneumococcal conjugate 10-valent routine immunization in Brazilian children.

Ana Lucia Sartori1, Ruth Minamisava2, Eliane Terezinha Afonso3, Gabriela Moreira Policena4, Grécia Carolina Pessoni5, Ana Luiza Bierrenbach4, Ana Lucia Andrade4.   

Abstract

BACKGROUND: Vaccination coverage is the usual metrics to evaluate the immunization programs performance. For the 10-valent pneumococcal conjugate (PCV10) vaccine, measuring the delay of vaccination is also important, particularly as younger children are at increased risk of disease. Routinely collected administrative data was used to assess the timeliness of PCV10 vaccination, and the factors associated with delay to receive the first and second doses, and the completion of the PCV10 3+1 schedule.
METHODS: A population-based retrospective cohort study was conducted with children born in 2012 in Central Brazil. Children who received the PCV10 first dose in public health services were followed-up until 23months of age. Timeliness of receiving each PCV10 dose at any given age was defined as receiving the dose within 28days grace period from the recommended age by the National Immunization Program. Log-binomial regression models were used to examine risk factors for delays of the first dose and the completion PCV10 3+1 schedule.
RESULTS: In total, 14,282 children were included in the cohort of study. Delayed vaccination occurred in 9.4%, 23.8%, 36.8% and 39.9% children for the first, second, third and the booster doses, respectively. A total of 1912 children (12.8% of the cohort) were not adequately vaccinated at the 6months of life; 1,071 (7%) received the second dose after 6months of age, 784 (5.4%) did not receive the second dose, and 57 (0.4%) received the first dose after six months of life.
CONCLUSION: A considerable delay was found in PCV10 third and booster doses. Almost 2 thousand children had not received the recommended PCV10 doses at 6months of age. Timeliness of vaccination is an issue in Brazil although high vaccination coverages.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Administrative data; Children; Pneumococcal vaccines; Timeliness; Vaccination

Mesh:

Substances:

Year:  2017        PMID: 28108230     DOI: 10.1016/j.vaccine.2017.01.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil.

Authors:  Joshua L Warren; Kayoko Shioda; Esra Kürüm; Cynthia Schuck-Paim; Roger Lustig; Robert J Taylor; Lone Simonsen; Daniel M Weinberger
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

2.  Sample study protocol for adapting and translating the 5C scale to assess the psychological antecedents of vaccination.

Authors:  Cornelia Betsch; Katrine Bach Habersaat; Sergei Deshevoi; Dorothee Heinemeier; Nikolay Briko; Natalia Kostenko; Janusz Kocik; Robert Böhm; Ingo Zettler; Charles Shey Wiysonge; Ève Dubé; Arnaud Gagneur; Elisabeth Botelho-Nevers; Amandine Gagneux-Brunon; Jonas Sivelä
Journal:  BMJ Open       Date:  2020-03-10       Impact factor: 2.692

3.  Vaccination timeliness and delay in low- and middle-income countries: a systematic review of the literature, 2007-2017.

Authors:  Nina B Masters; Abram L Wagner; Matthew L Boulton
Journal:  Hum Vaccin Immunother       Date:  2019-06-12       Impact factor: 3.452

4.  Descriptive analysis of routine childhood immunisation timeliness in the Western Cape, South Africa.

Authors:  Ntombifuthi Blose; Edina Amponsah-Dacosta; Benjamin M Kagina; Rudzani Muloiwa
Journal:  Vaccine X       Date:  2021-12-13

5.  Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.

Authors:  Adriana Guzman-Holst; Eliana de Barros; Pilar Rubio; Rodrigo DeAntonio; Otavio Cintra; Ariane Abreu
Journal:  Hum Vaccin Immunother       Date:  2021-03-18       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.